Einzeltreffer — DigiBib

Background: We analyzed the relationship between prostate cancer outcomes and pretreatment clinical factors and developed a prognostic nomogram of overall survival (OS) of patients with bone metastasis.

Methods: From 1993 to 2011, 463 consecutive patients were treated for bone-metastatic prostate cancer. Data sets from 361 patients were used to develop a nomogram (training data), and data sets of 102 patients were used for validation of the nomogram (validation data). Using the external validation data set, the nomogram was assessed for discriminatory ability, and the predictions were assessed for calibration accuracy by plotting actual survival against predicted risk.

Results: Of the 361 patients in the training data set, 205 (56.8%) patients died, 169 (46.8%) deaths of which were due to prostate cancer. The median follow-up period was 55.2 months. In the multivariate analysis, patient age, serum prostate-specific antigen level, clinical T stage, extent of disease on bone scan, and biopsy Gleason sum were independent prognostic factors. We developed a prognostic model comprising these five factors for patients with bone-metastatic prostate cancer. This nomogram can be used to estimate 1-, 3-, and 5-year survival probability. External validation of this model using 102 validation data sets showed reasonable accuracy (concordance index, 0.719).

Conclusion: Our pretreatment prognostic nomogram might be useful for Japanese patients with bone-metastatic prostate cancer.

Titel:	Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer.
Autor/in / Beteiligte Person:	Miyoshi, Y ; Noguchi, K ; Yanagisawa, M ; Taguri, M ; Morita, S ; Ikeda, I ; Fujinami, K ; Miura, T ; Kobayashi, K ; Uemura, H
Link:	Full Text Finder (Volltext)
Zeitschrift:	BMC cancer, Jg. 15 (2015-05-01), S. 338
Veröffentlichung:	London : BioMed Central, [2001-, 2015
Medientyp:	academicJournal
ISSN:	1471-2407 (electronic)
DOI:	10.1186/s12885-015-1330-x
Schlagwort:	Adult Aged Aged, 80 and over Bone Neoplasms blood Bone Neoplasms secondary Disease-Free Survival Humans Japan Kaplan-Meier Estimate Male Middle Aged Neoplasm Grading Nomograms Prostate-Specific Antigen blood Prostatectomy Prostatic Neoplasms blood Prostatic Neoplasms surgery Bone Neoplasms pathology Prognosis Prostatic Neoplasms pathology
Sonstiges:	Nachgewiesen in: MEDLINE Sprachen: English Publication Type: Journal Article; Research Support, Non-U.S. Gov't Language: English [BMC Cancer] 2015 May 01; Vol. 15, pp. 338. <i>Date of Electronic Publication: </i>2015 May 01. MeSH Terms: Prognosis* ; Bone Neoplasms / pathology ; Prostatic Neoplasms / pathology ; Adult ; Aged ; Aged, 80 and over ; Bone Neoplasms / blood ; Bone Neoplasms / secondary ; Disease-Free Survival ; Humans ; Japan ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Grading ; Nomograms ; Prostate-Specific Antigen / blood ; Prostatectomy ; Prostatic Neoplasms / blood ; Prostatic Neoplasms / surgery References: Int J Clin Oncol. 2005 Jun;10(3):182-6. (PMID: 15990966) ; J Clin Oncol. 2009 Jun 10;27(17):2766-71. (PMID: 19380448) ; Scand J Urol Nephrol. 2009;43(4):265-70. (PMID: 19382005) ; N Engl J Med. 2011 May 26;364(21):1995-2005. (PMID: 21612468) ; J Clin Oncol. 2003 Apr 1;21(7):1232-7. (PMID: 12663709) ; Lancet. 2010 Oct 2;376(9747):1147-54. (PMID: 20888992) ; J Clin Oncol. 2008 Mar 10;26(8):1364-70. (PMID: 18323559) ; BJU Int. 2010 Aug;106(4):462-9. (PMID: 20346033) ; Expert Rev Pharmacoecon Outcomes Res. 2014 Apr;14(2):175-9. (PMID: 24564607) ; Urology. 2006 Dec;68(6):1268-74. (PMID: 17169648) ; Lancet. 2000 Apr 29;355(9214):1491-8. (PMID: 10801170) ; Lancet. 2010 Apr 24;375(9724):1437-46. (PMID: 20398925) ; J Clin Oncol. 2009 Nov 10;27(32):5431-8. (PMID: 19805692) ; J Urol. 1998 Oct;160(4):1220-9. (PMID: 9751323) ; J Clin Oncol. 2002 Oct 1;20(19):3972-82. (PMID: 12351594) ; N Engl J Med. 1998 Oct 8;339(15):1036-42. (PMID: 9761805) ; N Engl J Med. 2004 Oct 7;351(15):1513-20. (PMID: 15470214) ; J Clin Oncol. 1997 Jan;15(1):382-8. (PMID: 8996165) ; Clin Cancer Res. 2010 Jan 1;16(1):203-11. (PMID: 20008841) ; Jpn J Clin Oncol. 2014 Apr;44(4):388-96. (PMID: 24503029) ; J Clin Oncol. 2009 Sep 10;27(26):4306-13. (PMID: 19667269) ; Cancer. 1988 Jan 1;61(1):195-202. (PMID: 3334948) ; N Engl J Med. 2010 Jul 29;363(5):411-22. (PMID: 20818862) ; Clin Cancer Res. 2007 Nov 1;13(21):6396-403. (PMID: 17975152) Substance Nomenclature: EC 3.4.21.77 (Prostate-Specific Antigen) Entry Date(s): Date Created: 20150502 Date Completed: 20160125 Latest Revision: 20240530 Update Code: 20240530 PubMed Central ID: PMC4423138

Klicken Sie ein Format an und speichern Sie dann die Daten oder geben Sie eine Empfänger-Adresse ein und lassen Sie sich per Email zusenden.

BibTeX Citavi, JabRef, u.a.
(Literaturverwaltung)

PDF kein Volltext!
(Merkzettel, Notizen)

RIS Endnote, Citavi u.a.
(Literaturverwaltung)

MODS
(XML zur Weiterverarbeitung)

oder

Wählen Sie das für Sie passende Zitationsformat und kopieren Sie es dann in die Zwischenablage, lassen es sich per Mail zusenden oder speichern es als PDF-Datei.

Gewünschter Zitations-Stil:

oder

Bitte prüfen Sie, ob die Zitation formal korrekt ist, bevor Sie sie in einer Arbeit verwenden. Benutzen Sie gegebenenfalls den "Exportieren"-Dialog, wenn Sie ein Literaturverwaltungsprogramm verwenden und die Zitat-Angaben selbst formatieren wollen.

Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer.